Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS · Delayed Price · Currency is USD
0.1928
+0.0028 (1.47%)
Apr 23, 2026, 12:56 PM EST
Northwest Biotherapeutics Revenue
In the year 2025, Northwest Biotherapeutics had annual revenue of $1.38M, down -0.29%. Northwest Biotherapeutics had revenue of $672.00K in the quarter ending December 31, 2025, with 190.91% growth.
Revenue
1.38M
Revenue Growth
-0.29%
P/S Ratio
229.27
Revenue / Employee
13.12K
Employees
25
Market Cap
315.93M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.38M | -4.00K | -0.29% |
| Dec 31, 2024 | 1.38M | -550.00K | -28.47% |
| Dec 31, 2023 | 1.93M | 249.00K | 14.80% |
| Dec 31, 2022 | 1.68M | 678.00K | 67.46% |
| Dec 31, 2021 | 1.01M | -286.00K | -22.15% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vaxart | 237.26M |
| BioStem Technologies | 47.48M |
| Nuo Therapeutics | 3.31M |
| Harvard Apparatus Regenerative Technology | 704.00K |
| Silence Therapeutics | 559.00K |
| Provectus Biopharmaceuticals | 336.11K |
| Arch Biopartners | 115.29K |
Northwest Biotherapeutics News
- 2 days ago - Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic - PRNewsWire
- 5 months ago - Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility - PRNewsWire
- 6 months ago - Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed - PRNewsWire
- 8 months ago - Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd. - PRNewsWire
- 8 months ago - Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman - PRNewsWire
- 11 months ago - Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments - PRNewsWire
- 1 year ago - Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing - PRNewsWire
- 1 year ago - Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities - PRNewsWire